Transforming The Management Of Critical Bleeding and Clotting

HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra, that provides actionable information to guide the management of critical bleeding and clotting.

Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings. We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to rapidly choose the right treatment, dramatically improving outcomes and lowering treatment costs.

Our Products

The Quantra™ is a rapid, easy-to-use, point-of-care diagnostic platform that fully characterizes and guides the management of critical bleeding.
Learn more.

Our Technology

Our patented SEER sonorheometry technology quantifies coagulation by measuring the evolving stiffness of clotting blood.
Learn more.

Our Leadership

Our team has a proven track record of successfully developing and bringing to market innovative medical devices.
Learn more.

Blood cells

Studies show that use of comprehensive point-of-care coagulation testing in surgical settings leads to:

Improved clinical outcomes

  • Fewer transfusions
  • Fewer complications

Reduced cost of care

  • Reduced blood product utilization
  • Shorter inpatient stays

NEWSFEED

HemoSonics Opens New Facility in Durham, NC

Charlottesville, VA – December 7, 2015 – HemoSonics, a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced that it has opened a new facility in Durham, NC. “The expertise in hemostasis in the Research Triangle is unparalleled, and we are excited to have a new facility that will leverage the wealth of talent in the region. This new facility will support the final stage of development and clinical testing of our Quantra™ platform,” said Tim Fischer, CEO of HemoSonics. “The university ecosystem provides ample sites for clinical testing and we have built out a strong team to fuel our future growth.” The Durham Facility currently has 11 employees. The facility will focus on software development, system engineering, reagent development, and clinical... read more

SEER Technology Published in Annals of Biomedical Engineering and to be Presented at IEEE International Ultrasonics Symposium

Charlottesville, VA – October 19, 2015 – HemoSonics, a medical device company developing and commercializing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced that a paper detailing its novel SEER technology was published in the Annals of Biomedical Engineering. The paper, Sonic Estimation of Elasticity via Resonance: A New Method of Assessing Hemostasis, details the core technology behind the Quantra™, a point-of-care in vitro diagnostic platform that measures blood clot formation and breakdown and provides actionable information to guide the management of critical bleeding and clotting. SEER uses ultrasound to initiate and measure mechanical resonance in a clotting blood sample. The characteristics of this resonance are analyzed to precisely measure the evolving clot stiffness. SEER requires no moving parts and uses commodity electronics. An abstract detailing HemoSonics’ SEER technology was also accepted for the IEEE International Ultrasonics Symposium. The conference will be held in Taipei, Taiwan, on October 21-24th, 2015. Paper Citation Corey, FS, and WF Walker. “Sonic Estimation of Elasticity Via Resonance: A New Method of Assessing Hemostasis.” Annals of biomedical engineering (2015)doi:10.1007/s10439-015-1460-y. Abstract Details Title: Sonic Estimation of Elasticity via Resonance (SEER): Initial Results from a New Method of Assessing Hemostasis Authors: FS Corey, WF Walker Session: 3I – MEL: Towards clinical application of elasticity imaging Date: October 24, 2015, 10:30am –... read more

HemoSonics appoints Josep Manent to Board of Managers

Former CEO of Instrumentation Laboratory Adds Depth to Board Charlottesville, VA – September 17, 2015 – HemoSonics, a medical device company developing and commercializing a point-of-care diagnostic platform to guide the management of critical bleeding in surgery and acute care settings, announced that Josep Manent has been elected to its Board of Managers. Mr. Manent has over 35 years of business, financial, product development and marketing experience in the in vitro diagnostics (IVD) industry.  He previously held senior management positions in the Werfen Life Group, a family of leading companies in the IVD sector. Most recently, he served as the CEO of Instrumentation Laboratory (IL), a leader in critical care, hemostasis and point-of-care diagnostics, from 1999 until his retirement in 2011.  Under his leadership at IL, the company returned to profitability and became a world leader in hemostasis and point-of-care through a combination of creative customer targeting, efficient manufacturing and a focus on innovative product development. “Josep brings an unparalleled depth of experience and industry knowledge in the in vitro diagnostics space,” said William P. Moffitt, Chairman of the Board of HemoSonics. “His perspective, global reputation and insight will be invaluable as we initiate commercialization of the Quantra™ platform and seek to accelerate shareholder value.” Prior to his employment with Werfen, Mr. Manent was a co-founder of Biokit, a developer of systems and immunoassay tests for clinical laboratories, and served as its President and General Manager for 20 years.  Biokit was acquired by Werfen. Mr. Manent received his MBA at ESADE Business School and participated in Executive and Marketing programs at Stanford University. “I believe HemoSonics has a unique... read more

HemoSonics Awarded $1M Phase II Grant from the US Air Force

Phase II to Validate Use of the QuantraTM for Measuring Platelet Impairment Charlottesville, VA – August 7, 2015 – HemoSonics, a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced that it received a $1 million Phase II grant from the United States Department of the Air Force. The Phase II grant will help fund the development of the Quantra™  and the evaluation of its clinical utility in assessing coagulopathies in trauma. “This grant validates the need for a fast, comprehensive and accurate point of care test to measure platelet impairment and guide treatment of critical bleeding in trauma settings,” said Francesco Viola, Chief Science Officer of HemoSonics. “These funds will support the continued development of our Quantra™  platform, designed to deliver actionable information to guide the management of critical bleeding and clotting in critical care settings.”  ... read more

PennsylvaniaBIO